The company provides end-to-end healthcare infrastructure solutions, including the design and installation of modular operation theaters and critical care units, while also distributing high-end medical equipment for global brands.
The company claims a moat based on proprietary technology partnerships and high entry barriers for government tenders; however, the lack of pricing power and high dependency on government budgeting cycles result in volatile margins and poor cash conversion.
Capital has been primarily directed toward working capital to support long-cycle government projects and a new manufacturing facility under a subsidiary, though high receivables suggest inefficient capital rotation.
The business collapsed under the weight of its own balance sheet as the gap between accounting profits and actual cash widened into a chasm. Despite reporting revenue growth, the company's reliance on government tenders led to a terminal liquidity trap where receivables consumed all operating capital. When government budgeting cycles tightened, the lack of pricing power prevented the company from passing on costs, while the high concentration of unpaid invoices forced a dilutive equity raise or a debt spiral to fund basic operations. The inability to convert earnings into cash eventually revealed the business as a treadmill that required more capital to stay still than it could ever hope to return to shareholders.
RichFakir rates Aprameya Engineering Ltd's business quality as poor — 33/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, Aprameya Engineering Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Aprameya Engineering Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Aprameya Engineering Ltd's fair value is about ₹32 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →